Clair W K, Chylack L T, Cook E F, Goldman L
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Br J Ophthalmol. 1989 Mar;73(3):173-6. doi: 10.1136/bjo.73.3.173.
Several reports have suggested an association between chronic allopurinol ingestion and cortical and subcapsular cataract formation. To examine this possibility we identified 51 allopurinol users and compared their lenses with those of 76 patients who did not use allopurinol. The existence of lens opacities and the level of visual acuity were assessed by review of medical records or by prospective ophthalmic examinations; in both phases of the study the examiners were blinded as to the patient's use or non-use of allopurinol. Three different outcomes were considered: formation of any cataract, formation of a posterior subcapsular cataract, and formation of a cataract contributing to a corrected visual acuity of 20/30 or worse. The risk ratio for the formation of any cataract was 1.3 (95% confidence interval: 0.8, 2.0), the risk ratio for the formation of a posterior subcapsular cataract was 0.9 (0.3, 2.0), and the risk ratio for the formation of a cataract contributing to a loss of visual acuity was 1.3 (0.6, 2.9). None of these risk ratios was changed appreciably after controlling for age, sex, hypertension, or diabetes. Thus, after a mean of 6.9 years of allopurinol use, we found no evidence to confirm that allopurinol users were at higher risk of acquiring cataracts.
几份报告表明,长期服用别嘌醇与皮质性和后囊下白内障的形成之间存在关联。为了检验这种可能性,我们确定了51名别嘌醇使用者,并将他们的晶状体与76名未使用别嘌醇的患者的晶状体进行了比较。通过查阅病历或进行前瞻性眼科检查来评估晶状体混浊的存在情况和视力水平;在研究的两个阶段,检查人员都不知道患者是否使用了别嘌醇。考虑了三种不同的结果:任何白内障的形成、后囊下白内障的形成以及导致矫正视力为20/30或更差的白内障的形成。任何白内障形成的风险比为1.3(95%置信区间:0.8,2.0),后囊下白内障形成的风险比为0.9(0.3,2.0),导致视力丧失的白内障形成的风险比为1.3(0.6,2.9)。在控制年龄、性别、高血压或糖尿病后,这些风险比均未发生明显变化。因此,在平均使用别嘌醇6.9年后,我们没有发现证据证实别嘌醇使用者患白内障的风险更高。